Versant Venture Management 13F-HR Quarterly holdings report by institutional manager

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number:		3235-0006
Expires:	Oct 31, 2018
Estimated average burden
hours per response:		23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8
			VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x$1000)	PRN AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
Clovis Oncology, Inc.	Common Stock	189464100	5,589,748	407,416	SH		OTR		0	407,416	0
CymaBay Therapeutics, Inc.	Common Stock	23257D103	1,824,566	1,048,601	SH		OTR		0	1,048,601	0
Achaogen, Inc.	Common Stock	004449104	4,855,566	1,281,152	SH		OTR		0	1,281,152	0
Ocular Therapeutix, Inc.	Common Stock	67576A100	10,966,151	2,215,384	SH		OTR		0	2,215,384	0
Glaukos Corporation	Common Stock	377322102	75,436,483	2,586,985	SH		OTR		0	2,586,985	0